Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2002

View Archived Issues

Studies of pioglitazone in liver diseases discussed at AASLD meeting

Entecavir reportedly superior to lamivudine in HBV-infected patients

Amantadine in combination therapies for hepatitis C

Novel inhibitors of CDK and GSK-3 identified by Schering researchers

Series of histamine H3 antagonists for use in cognitive disorders reported by Abbott

Altana Pharma claims novel series of tryptase inhibitors with utility in airways disorders

New 5-HT2C agonists for erectile dysfunction and other disorders under study at Yamanouchi

IL-6 production inhibitors in early development at Ono

Novel substance P antagonists covered by Takeda patent

New alphavbeta3 antagonists in development at Dainippon

Potential use of vaccines in advanced prostate cancer

Albuferon in chronic hepatitis C

Zileuton reported to improve airways inflammation in cystic fibrosis

Symptom relief achieved with tiotropium in mild COPD

Oral factor Xa inhibitor enters phase I study for the treatment of thrombotic diseases

First approval obtained for Cialis

Endo and Durect to collaborate in the area of pain management

Bristol-Myers Squibb signs NF-kB license agreement with Ariad

CeNeS agrees to outlicense potential treatment for MS to Acorda

Neurocrine Biosciences reports positive results from phase III trial with indiplon-IR

Incyte Genomics to acquire Maxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...